Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice

References

• Ali O. Genetics of type 2 diabetes. World J Diabetes. 2013;4(4):114–123. doi:10.4239/wjd.v4.i4.114
   PubMedGoogle Scholar
• Gujral UP, Pradeepa R, Weber MB, Narayan KMV, Mohan V. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann NY Acad Sc. 2013;1281(1):51–63. doi:10.1111/j.1749-6632.2012.06838.x
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium; 2019. Available from: https://www.diabetesatlas.org. Accessed October 11, 2021.
   Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(3):1047–1053. doi:10.2337/diacare.27.5.1047
   Web of Science ®Google Scholar
• Joshi SR, Das AK, Vijay VJ, Mohan V. Challenges in diabetes care in India: sheer numbers, lack of awareness and inadequate control. J Assoc Physicians India. 2008;56:443–450.
   Google Scholar
• Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, Javier Del Cañizo-Gómez F. Update on the treatment of type 2 diabetes mellitus. World J Diabetes. 2016;7(17):354–395. doi:10.4239/wjd.v7.i17.354
   PubMed Web of Science ®Google Scholar
• Zeggini E, Scott LJ, Saxena R, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet. 2008;40(5):638–645. doi:10.1038/ng.120
   PubMed Web of Science ®Google Scholar
• Kooner JS, Saleheen D, Sim X, et al. Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci. Nat Genet. 2011;43(10):984–989. doi:10.1038/ng.921
   PubMed Web of Science ®Google Scholar
• Voight BF, Scott LJ, Steinthorsdottir V, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42(7):579–589. doi:10.1038/ng.609
   PubMed Web of Science ®Google Scholar
• Radha V, Vimaleswaran KS, Ayyappa KA, Mohan V. Association of lipoprotein lipase gene polymorphisms with obesity and type 2 diabetes in an Asian Indian population. Int J Obes. 2007;31(6):913–918. doi:10.1038/sj.ijo.0803547
   Web of Science ®Google Scholar
• Vimaleswaran KS, Radha V, Ramya K, et al. A novel association of a polymorphism in the first intron of adiponectin gene with type 2 diabetes, obesity and hypoadiponectinemia in Asian Indians. Hum Genet. 2008;123(6):599–605. doi:10.1007/s00439-008-0506-8
   Web of Science ®Google Scholar
• Been LF, Hatfield JL, Shankar A, et al. A low frequency variant within the GWAS locus of MTNR1B affects fasting glucose concentrations: genetic risk is modulated by obesity. Nutr Metab Cardiovasc Dis. 2012;22(11):944–951. doi:10.1016/j.numecd.2011.01.006
   Web of Science ®Google Scholar
• Tabassum R, Mahajan A, Chauhan G, et al. Evaluation of DOK5 as a susceptibility gene for type 2 diabetes and obesity in North Indian population. BMC Med Genet. 2010;11:35. doi:10.1186/1471-2350-11-35
   Web of Science ®Google Scholar
• Mahajan A, Tabassum R, Srechavali E, et al. Obesity-dependent association of TNF-LTA locus with type 2 diabetes in North Indians. J Mol Med. 2010;88(5):515–522. doi:10.1007/s00109-010-0594-5
   Web of Science ®Google Scholar
• Ramya K, Radha V, Ghosh S, Majumder PP, Mohan V. Genetic variations in the FTO gene are associated with type 2 diabetes and obesity in South Indians (CURES-79). Diabetes Technol Ther. 2011;13(1):33–42. doi:10.1089/dia.2010.0071
   PubMed Web of Science ®Google Scholar
• Chauhan G, Kaur I, Tabassum R, et al. Common variants of homocysteine metabolism pathway genes and risk of type 2 diabetes and related traits in Indians. Exp Diabetes Res. 2012;2012:960318. doi:10.1155/2012/960318
   Google Scholar
• Prakash Dwivedi O, Tabassum R, Chauhan G, et al. Strong influence of variants near MC4R on adiposity in children and adults: a cross-sectional study in Indian population. J Hum Genet. 2013;58(1):27–32. doi:10.1038/jhg.2012.129
   PubMed Web of Science ®Google Scholar
• Yajnik CS, Janipalli CS, Bhaskar S, et al. FTO gene variants are strongly associated with type 2 diabetes in South Asian Indians. Diabetologia. 2009;52(2):247–252. doi:10.1007/s00125-008-1186-6
   PubMed Web of Science ®Google Scholar
• Cassell PG, Neverova M, Janmohamed S, et al. An uncoupling protein 2 gene variant is associated with a raised body mass index but not Type II diabetes. Diabetologia. 1999;42(6):688–692. doi:10.1007/s001250051216
   Web of Science ®Google Scholar
• Taylor AE, Sandeep MN, Janipalli CS, et al. Associations of FTO and MC4R variants with obesity traits in Indians and the role of rural/urban environment as a possible effect modifier. J Obes. 2011;2011:307542. doi:10.1155/2011/307542
   PubMedGoogle Scholar
• Gupta V, Vinay DG, Sovio U, et al. Association study of 25 type 2 diabetes related loci with measures of obesity in Indian Sib Pairs. PLoS One. 2013;8(1):e53944. doi:10.1371/journal.pone.0053944
   Web of Science ®Google Scholar
• Rees SD, Hydrie MZI, O’Hare JP, et al. Effects of 16 genetic variants on fasting glucose and type 2 diabetes in South Asians: ADCY5 and GLIS3 variants may predispose to type 2 diabetes. PLoS One. 2011;6(9):e24710. doi:10.1371/journal.pone.0024710
   PubMed Web of Science ®Google Scholar
• Chandak GR, Janipalli CS, Bhaskar S, et al. Common variants in the TCF7L2 gene are strongly associated with type 2 diabetes mellitus in the Indian population. Diabetologia. 2007;50(1):63–67. doi:10.1007/s00125-006-0502-2
   Web of Science ®Google Scholar
• Ali S, Chopra R, Manvati S, et al. Replication of type 2 diabetes candidate genes variations in three geographically unrelated Indian population groups. PLoS One. 2013;8(3):e58881. doi:10.1371/journal.pone.0058881
   Web of Science ®Google Scholar
• Salman M, Dasgupta S, Cholendra A, et al. MTNR1B gene polymorphisms and susceptibility to Type 2 Diabetes: a pilot study in South Indians. Gene. 2015;566(2):189–193. doi:10.1016/j.gene.2015.04.064
   PubMed Web of Science ®Google Scholar
• Bhatti GK, Kaur S, Vijayvergiya R, et al. ENPP1 K121Q functional variant enhances susceptibility to insulin resistance and dyslipidemia with metabolic syndrome in Asian Indians. Int J Diabetes Metab. 2018;24:8–15. doi:10.1159/000492478
   Google Scholar
• Chavali S, Mahajan A, Tabassum R, et al. Association of variants in genes involved in pancreatic Β-cell development and function with type 2 diabetes in North Indians. J Hum Genet. 2011;56(10):695–700. doi:10.1038/jhg.2011.83
   PubMed Web of Science ®Google Scholar
• Chauhan G, Spurgeon CJ, Tabassum R, et al. Impact of common variants of PPARG, KCNJ11, TCF7L2, SLC30A8, HHEX, CDKN2A, IGF2BP2, and CDKAL1 on the risk of type 2 diabetes in 5,164 Indians. Diabetes. 2010;59(8):2068–2074. doi:10.2337/db09-1386
   Web of Science ®Google Scholar
• Srivastava N, Prakash J, Lakhan R, Agarwal CG, Pant DC, Mittal B. A common polymorphism in the promoter of UCP2 is associated with obesity and hyperinsulenemia in northern Indians. Mol Cell Biochem. 2010;337(1–2):293–298. doi:10.1007/s11010-009-0311-2
   Web of Science ®Google Scholar
• Gupta A, Gupta V, Singh AK, et al. Interleukin-6 G-174C gene polymorphism and serum resistin levels in North Indian women: potential risk of metabolic syndrome. Hum Exp Toxicol. 2011;30(10):1445–1453. doi:10.1177/0960327110393763
   Web of Science ®Google Scholar
• Vimaleswaran KS, Radha V, Anjana M, et al. Effect of polymorphisms in the PPARGC1A gene on body fat in Asian Indians. Int J Obes. 2006;30(6):884–891. doi:10.1038/sj.ijo.0803228
   Web of Science ®Google Scholar
• Gomathi P, Samarth AP, Raj NBAJ, et al. The −866G/A polymorphism in the promoter of the UCP2 gene is associated with risk for type 2 diabetes and with decreased insulin levels. Gene. 2019;701:125–130. doi:10.1016/j.gene.2019.03.041
   Web of Science ®Google Scholar
• Stančáková A, Laakso M. Genetics of type 2 diabetes. Endocr Dev. 2016;31:203–220. doi:10.1159/000439418
   PubMedGoogle Scholar
• Prasad RB, Groop L. Genetics of type 2 diabetes—pitfalls and possibilities. Genes. 2015;6(1):87–123. doi:10.3390/genes6010087
   Web of Science ®Google Scholar
• Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20(3):284–287. doi:10.1038/3099
   PubMed Web of Science ®Google Scholar
• Schwanstecher C, Schwanstecher M. Nucleotide sensitivity of pancreatic ATP-sensitive potassium channels and type 2 diabetes. Diabetes. 2002;51(Suppl 3):S358–S362. doi:10.2337/diabetes.51.2007.s358
   Web of Science ®Google Scholar
• Hani EH, Boutin P, Durand E, et al. Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR): a meta-analysis suggests a role in the polygenic basis of Type II diabetes mellitus in Caucasians. Diabetologia. 1998;41:1511–1515. doi:10.1007/s001250051098
   PubMed Web of Science ®Google Scholar
• Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med. 2004;350(18):1838–1849. doi:10.1056/nejmoa032922
   PubMed Web of Science ®Google Scholar
• Almind K, Bj o Rbaek C, Vestergaard H, Hansen T, Echwald S, Pedersen O. Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. Lancet. 1993;342(8875):828–832. doi:10.1016/0140-6736(93)92694-O
   Web of Science ®Google Scholar
• Le Fur S, Le Stunff C, Bougnères P. Increased insulin resistance in obese children who have both 972 IRS-1 and 1057 IRS-2 polymorphisms. Diabetes. 2002;51(Suppl 3):S304–S307. doi:10.2337/diabetes.51.2007.s304
   PubMed Web of Science ®Google Scholar
• Cheng S, Wu Y, Wu W, Zhang D. Association of rs734312 and rs10010131 polymorphisms in WFS1 gene with type 2 diabetes mellitus: a meta-analysis. Endocr J. 2013;60(4):441–447. doi:10.1507/endocrj.ej12-0325
   Web of Science ®Google Scholar
• Giuffrida FMA, Furuzawa GK, Kasamatsu TS, Oliveira MM, Reis AF, Dib SA. HNF1A gene polymorphisms and cardiovascular risk factors in individuals with late-onset autosomal dominant diabetes: a cross-sectional study. Cardiovasc Diabetol. 2009;8:28. doi:10.1186/1475-2840-8-28
   Web of Science ®Google Scholar
• Abate N, Chandalia M, Satija P, et al. ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes. Diabetes. 2005;54(4):1207–1213. doi:10.2337/diabetes.54.4.1207
   Web of Science ®Google Scholar
• Moore AF, Jablonski KA, Mason CC, et al. The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program. J Clin Endocrinol Metab. 2009;94(2):449–455. doi:10.1210/jc.2008-1583
   Web of Science ®Google Scholar
• Li YY. ENPP1 K121Q polymorphism and type 2 diabetes mellitus in the Chinese population: a meta-analysis including 11 855 subjects. Metabolism. 2012;61(5):625–633. doi:10.1016/j.metabol.2011.10.002
   PubMed Web of Science ®Google Scholar
• Bhatti JS, Bhatti GK, Mastana SS, Ralhan S, Joshi A, Tewari R. ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes in North Indians. Mol Cell Biochem. 2010;345(1–2):249–257. doi:10.1007/s11010-010-0579-2
   PubMed Web of Science ®Google Scholar
• International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature. 2004;431(7011):931–945. doi:10.1038/nature03001
   PubMed Web of Science ®Google Scholar
• International HapMap Consortium. The International HapMap Project. Nature. 2003;426(6968):789–796. doi:10.1038/nature02168
   PubMed Web of Science ®Google Scholar
• Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007;445(7130):881–885. doi:10.1038/nature05616
   PubMed Web of Science ®Google Scholar
• Shin SY, Fauman EB, Petersen AK, et al. An atlas of genetic influences on human blood metabolites. Nat Genet. 2014;46(6):543–550. doi:10.1038/ng.2982
   PubMed Web of Science ®Google Scholar
• Smith RJ, Nathan DM, Arslanian SA, Groop L, Rizza RA, Rotter JI. Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocrinol Metab. 2010;95(4):1566–1574. doi:10.1210/jc.2009-1966
   PubMed Web of Science ®Google Scholar
• Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. Br Med J. 2007;334(7588):299–302. doi:10.1136/bmj.39063.689375.55
   PubMed Web of Science ®Google Scholar
• Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6(5):361–369. doi:10.1016/S2213-8587(18)30051-2
   PubMed Web of Science ®Google Scholar
• Zou J, Huss M, Abid A, Mohammadi P, Torkamani A, Telenti A. A primer on deep learning in genomics. Nat Genet. 2019;51(1):12–18. doi:10.1038/s41588-018-0295-5
   PubMed Web of Science ®Google Scholar
• Ge S, Wang Y, Song M, et al. Type 2 diabetes mellitus: integrative analysis of multiomics data for biomarker discovery. OMICS. 2018;22(7):514–523. doi:10.1089/omi.2018.0053
   Web of Science ®Google Scholar
• Van Der Heijden AA, Rauh SP, Dekker JM, et al. The Hoorn Diabetes Care System (DCS) cohort. A prospective cohort of persons with type 2 diabetes treated in primary care in the Netherlands. BMJ Open. 2017;7(5):e015599. doi:10.1136/bmjopen-2016-015599
   Google Scholar
• Andrew H, Neil W, Demicco DA, et al. Analysis of efficacy and safety in patients aged 65–75 years at randomization collaborative atorvastatin diabetes study (CARDS). Diabetes Care. 2006;29(11):2378–2384. doi:10.2337/dc06-0872
   Web of Science ®Google Scholar
• Ikram MA, Brusselle GGO, Murad SD, et al. The Rotterdam Study: 2018 update on objectives, design and main results. Eur J Epidemiol. 2017;32(9):807–850. doi:10.1007/s10654-017-0321-4
   PubMed Web of Science ®Google Scholar
• Van Leeuwen N, Nijpels G, Becker ML, et al. A gene variant near ATM is significantly associated with metformin treatment response In type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia. 2012;55(7):1971–1977. doi:10.1007/s00125-012-2537-x
   PubMed Web of Science ®Google Scholar
• Shokri F, Ghaedi H, Ghafouri Fard S, et al. Impact of ATM and SLC22A1 polymorphisms on therapeutic response to metformin in Iranian diabetic patients. Int J Mol Cell Med. 2016;5(1):1–7.
   Google Scholar
• Out M, Becker ML, Van Schaik RH, Lehert P, Stehouwer CD, Kooy A. A gene variant near ATM affects the response to metformin and metformin plasma levels: a post hoc analysis of an RCT. Pharmacogenomics. 2018;19(8):715–726. doi:10.2217/pgs-2018-0010
   Web of Science ®Google Scholar
• Vilvanathan S, Gurusamy U, Mukta V, Das AK, Chandrasekaran A. Allele and genotype frequency of a genetic variant in ataxia telangiectasia mutated gene affecting glycemic response to metformin in South Indian population. Indian J Endocrinol Metab. 2014;18(6):850–854. doi:10.4103/2230-8210.119944
   Google Scholar
• Umamaheswaran G, Praveen RG, Damodaran SE, Das AK, Adithan C. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients. Clin Exp Med. 2015;15(4):511–517. doi:10.1007/s10238-014-0322-5
   PubMed Web of Science ®Google Scholar
• Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CNA, Pearson ER. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes. 2015;64(5):1786–1793. doi:10.2337/db14-1388
   PubMed Web of Science ®Google Scholar
• Sur D. A tale of genetic variation in the human slc22a1 gene encoding oct1 among type 2 diabetes mellitus population groups of West Bengal, India. IMPACT. 2014;2:97–106. doi:10.4172/1747-0862.C1.010
   Google Scholar
• Mato EPM, Guewo-Fokeng M, Faadiel Essop M, Owira PMO. Genetic polymorphisms of organic cation transporters 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes mellitus: a systematic review. Medicine. 2018;97(27):e11349. doi:10.1097/MD.0000000000011349
   Web of Science ®Google Scholar
• Reséndiz-Abarca CA, Flores-Alfaro E, Suárez-Sánchez F, et al. Altered glycemic control associated with polymorphisms in the SLC22A1 (OCT1) gene in a Mexican population with type 2 diabetes mellitus treated with metformin: a cohort study. J Clin Pharmacol. 2019;59(10):1384–1390. doi:10.1002/jcph.1425
   Web of Science ®Google Scholar
• Todd JN, Florez JC. An update on the pharmacogenomics of metformin: progress, problems and potential. Pharmacogenomics. 2014;15(4):529–539. doi:10.2217/pgs.14.21
   PubMed Web of Science ®Google Scholar
• Becker ML, Visser LE, Van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes. 2009;58(3):745–749. doi:10.2337/db08-1028
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009;86(3):299–306. doi:10.1038/clpt.2009.92
   PubMed Web of Science ®Google Scholar
• Al-Eitan LN, Almomani BA, Nassar AM, Elsaqa BZ, Saadeh NA. Metformin pharmacogenetics: effects of SLC22A1, SLC22A2, and SLC22A3 polymorphisms on glycemic control and HBA1c levels. J Pers Med. 2019;9(1):17. doi:10.3390/jpm9010017
   Web of Science ®Google Scholar
• Ghaffari-Cherati M, Mahrooz A, Hashemi-Soteh MB, Raheleh Hosseyni-Talei S, Alizadeh A, Nakhaei SM. Allele frequency and genotype distribution of a common variant in the 3´-untranslated region of the SLC22A3 gene in patients with type 2 diabetes: association with response to metformin. J Res Med Sci. 2016;21:92. doi:10.4103/1735-1995.192508
   PubMed Web of Science ®Google Scholar
• Rotroff DM, Yee SW, Zhou K, et al. Genetic variants in CPA6 and PRPF31 are associated with variation in response to metformin in individuals with type 2 diabetes. Diabetes. 2018;67(7):1428–1440. doi:10.2337/db17-1164
   PubMed Web of Science ®Google Scholar
• Dujic T, Bego T, Malenica M, et al. Effects of TCF7L2 rs7903146 variant on metformin response in patients with type 2 diabetes. Bosn J Basic Med Sci. 2019;19(4):368–374. doi:10.17305/bjbms.2019.4181
   Web of Science ®Google Scholar
• Dawed AY, Zhou K, van Leeuwen N, et al. Variation in the plasma membrane monoamine transporter (PMAT) (encoded by SLC29A4) and organic cation transporter 1 (OCT1) (encoded by SLC22A1) and gastrointestinal intolerance to metformin in type 2 diabetes: an IMI DIRECT study. Diabetes Care. 2019;42(6):1027–1033. doi:10.2337/dc18-2182
   PubMed Web of Science ®Google Scholar
• Becker ML, Visser LE, Trienekens PH, Hofman A, Van Schaik RHN, Stricker BHC. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther. 2008;83(2):288–292. doi:10.1038/sj.clpt.6100273
   PubMed Web of Science ®Google Scholar
• Weisnagel SJ, Rankinen T, Nadeau A, et al. Decreased fasting and oral glucose stimulated C-peptide in nondiabetic subjects with sequence variants in the sulfonylurea receptor 1 gene. Diabetes. 2001;50(3):697–702. doi:10.2337/diabetes.50.3.697
   PubMed Web of Science ®Google Scholar
• Venkatesan R, Bodhini D, Narayani N, Mohan V. Association study of the ABCC8 gene variants with type 2 diabetes in south Indians. Indian J Hum Genet. 2014;20(1):37–42. doi:10.4103/0971-6866.132752
   PubMedGoogle Scholar
• Javorsky M, Klimcakova L, Schroner Z, et al. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. Eur J Intern Med. 2012;23(3):245–249. doi:10.1016/j.ejim.2011.10.018
   PubMed Web of Science ®Google Scholar
• Loganadan NK, Huri HZ, Vethakkan SR, Hussein Z. Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation. Pharmacogenomics J. 2016;16(3):209–219. doi:10.1038/tpj.2015.95
   PubMed Web of Science ®Google Scholar
• Dhawan D, Padh H. Genetic variations in TCF7L2 influence therapeutic response to sulfonylureas in Indian diabetics. Diabetes Res Clin Pract. 2016;121:35–40. doi:10.1016/j.diabres.2016.08.018
   PubMed Web of Science ®Google Scholar
• Schroner Z, Javorsky M, Tkacova R, et al. Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(11):89–91. doi:10.1111/j.1463-1326.2010.01324.x
   Web of Science ®Google Scholar
• Holstein A, Hahn M, Körner A, Stumvoll M, Kovacs P. TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Med Genet. 2011;12:30. doi:10.1186/1471-2350-12-30
   PubMed Web of Science ®Google Scholar
• Chen ZR, He FZ, Liu MZ, et al. MIR4532 gene variant rs60432575 influences the expression of KCNJ11 and the sulfonylureas-stimulated insulin secretion. Endocrine. 2019;63(3):489–496. doi:10.1007/s12020-018-1754-6
   Web of Science ®Google Scholar
• Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756. doi:10.1016/j.cmet.2018.03.001
   PubMed Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487–493. doi:10.2337/dci19-0066
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl1):S98–S110. doi:10.2337/dc20-S009
   PubMed Web of Science ®Google Scholar
• Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016;18(3):203–216. doi:10.1111/dom.12591
   PubMed Web of Science ®Google Scholar
• Urgeová A, Javorský M, Klimčáková L, et al. Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors. Pharmacogenomics. 2020;21(5):317–323. doi:10.2217/pgs-2019-0147
   Web of Science ®Google Scholar
• Böhm A, Wagner R, Machicao F, et al. DPP4 gene variation affects GLP-1 secretion, insulin secretion, and glucose tolerance in humans with high body adiposity. PLoS One. 2017;12(7):e0181880. doi:10.1371/journal.pone.0181880
   Web of Science ®Google Scholar
• Jamaluddin JL, Huri HZ, Vethakkan SR. Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus. Pharmacogenomics. 2016;17(8):867–881. doi:10.2217/pgs-2016-0010
   PubMed Web of Science ®Google Scholar
• Gotthardová I, Javorský M, Klimčáková L, et al. KCNQ1 gene polymorphism is associated with glycaemic response to treatment with DPP-4 inhibitors. Diabetes Res Clin Pract. 2017;130:142–147. doi:10.1016/j.diabres.2017.05.018
   PubMed Web of Science ®Google Scholar
• Osada UN, Sunagawa H, Terauchi Y, Ueda S. A common susceptibility gene for type 2 diabetes is associated with drug response to a DPP-4 inhibitor: pharmacogenomic cohort in Okinawa Japan. PLoS One. 2016;11(5):e0154821. doi:10.1371/journal.pone.0154821
   PubMed Web of Science ®Google Scholar
• Liao WL, Lee WJ, Chen CC, et al. Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes. Oncotarget. 2017;8(11):18050–18058. doi:10.18632/oncotarget.14951
   PubMedGoogle Scholar
• Zimdahl H, Haupt A, Brendel M, et al. Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes. Pharmacogenet Genomics. 2017;27(4):135–142. doi:10.1097/FPC.0000000000000268
   PubMed Web of Science ®Google Scholar
• Enigk U, Breitfeld J, Schleinitz D, et al. Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis. Pharmacogenomics. 2011;12(8):1119–1126. doi:10.2217/pgs.11.69
   PubMed Web of Science ®Google Scholar
• Francke S, Mamidi RNVS, Solanki B, et al. In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. J Clin Pharmacol. 2015;55(9):1061–1072. doi:10.1002/jcph.506
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP-NIDDM trial: an international study on the efficacy of an α- glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Diabetes Care. 1998;21(10):1720–1725. doi:10.2337/diacare.21.10.1720
   Web of Science ®Google Scholar
• Andrulionytè L, Zacharova J, Chiasson JL, Laakso M. Common polymorphisms of the PPAR-γ2 (Pro12Ala) and PGC-1α (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia. 2004;47(12):2176–2184. doi:10.1007/s00125-004-1577-2
   Web of Science ®Google Scholar
• Hart LM, Fritsche A, Nijpels G, et al. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes. 2013;62(9):3275–3281. doi:10.2337/db13-0227
   PubMed Web of Science ®Google Scholar
• Kan H, Hyogo H, Ochi H, et al. Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res. 2016;46(3):E146–E153. doi:10.1111/hepr.12552
   Web of Science ®Google Scholar
• Chedid V, Vijayvargiya P, Carlson P, et al. Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: a pilot pharmacogenetics study. Neurogastroenterol Motil. 2018;30(7):e13313. doi:10.1111/nmo.13313
   Web of Science ®Google Scholar
• Lin CH, Lee YS, Huang YY, Hsieh SH, Chen ZS, Tsai CN. Polymorphisms of GLP-1 receptor gene and response to GLP-1 analogue in patients with poorly controlled type 2 diabetes. J Diabetes Res. 2015;2015:176949. doi:10.1155/2015/176949
   PubMed Web of Science ®Google Scholar
• Singh S, Usman K, Banerjee M. Pharmacogenetic studies update in type 2 diabetes mellitus. World J Diabetes. 2016;7(15):302–315. doi:10.4239/wjd.v7.i15.302
   Google Scholar
• Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther. 2003;74(4):380–387. doi:10.1016/S0009-9236(03)00228-5
   Web of Science ®Google Scholar
• Sheng FF, Dai XP, Qu J, et al. NAMPT −3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2011;38(8):550–554. doi:10.1111/j.1440-1681.2011.05548.x
   Web of Science ®Google Scholar
• Dai XP, Huang Q, Yin JY, et al. KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese Type 2 diabetic patients. Clin Exp Pharmacol Physiol. 2012;39(5):462–468. doi:10.1111/j.1440-1681.2012.05701.x
   Web of Science ®Google Scholar
• Wang T, Wang Y, Lv DM, et al. Effects of NOS1AP rs12742393 polymorphism on repaglinide response in Chinese patients with type 2 diabetes mellitus. Pharmacotherapy. 2014;34(2):131–139. doi:10.1002/phar.1379
   Web of Science ®Google Scholar
• Zhou X, Chen C, Yin D, et al. A variation in the ABCC8 gene is associated with type 2 diabetes mellitus and repaglinide efficacy in Chinese type 2 diabetes mellitus patients. Intern Med. 2019;58(16):2341–2347. doi:10.2169/internalmedicine.2133-18
   PubMed Web of Science ®Google Scholar
• Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE. Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol. 2008;153(4):636–645. doi:10.1038/sj.bjp.0707452
   Web of Science ®Google Scholar
• Chang TJ, Liu PH, Liang YC, et al. Genetic predisposition and nongenetic risk factors of thiazolidinedione-related edema in patients with type 2 diabetes. Pharmacogenet Genomics. 2011;21(12):829–836. doi:10.1097/FPC.0b013e32834bfff1
   Web of Science ®Google Scholar
• Zhang KH, Huang Q, Dai XP, et al. Effects of the peroxisome proliferator activated receptor-γ coactivator-1α (PGC-1α) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitus. J Clin Pharmacol. 2010;50(9):1022–1030. doi:10.1177/0091270009355159
   Web of Science ®Google Scholar
• Eun SK, So YP, Hyeong JK, et al. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther. 2005;78(2):202–208. doi:10.1016/j.clpt.2005.04.013
   Web of Science ®Google Scholar
• Hsieh MC, Der LK, Tien KJ, et al. Common polymorphisms of the peroxisome proliferator-activated receptor-γ (Pro12Ala) and peroxisome proliferator-activated receptor-γ coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. Metabolism. 2010;59(8):1139–1144. doi:10.1016/j.metabol.2009.10.030
   PubMed Web of Science ®Google Scholar
• Chen M, Hu C, Zhang R, et al. Association of PAX4 genetic variants with oral antidiabetic drugs efficacy in Chinese type 2 diabetes patients. Pharmacogenomics J. 2014;14(5):488–492. doi:10.1038/tpj.2014.18
   Web of Science ®Google Scholar
• Dawed AY, Donnelly L, Tavendale R, et al. CYP2C8 and SLCO1B1 variants and therapeutic response to thiazolidinediones in patients with Type 2 diabetes. Diabetes Care. 2016;39(11):1902–1908. doi:10.2337/dc15-2464
   PubMed Web of Science ®Google Scholar
• Hruska MW, Amico JA, Langaee TY, Ferrell RE, Fitzgerald SM, Frye RF. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. Br J Clin Pharmacol. 2005;59(1):70–79. doi:10.1111/j.1365-2125.2005.02263.x
   PubMed Web of Science ®Google Scholar
• Chung WK, Erion K, Florez JC, et al. Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63(9):1671–1693. doi:10.1007/s00125-020-05181-w
   Web of Science ®Google Scholar
• Della Corte CM, Ciaramella V, Di Mauro C, et al. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. Oncotarget. 2016;7(4):4265–4278. doi:10.18632/oncotarget.6559
   Google Scholar
• Morgillo F, Fasano M, Della Corte CM, et al. Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label Phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer. ESMO Open. 2017;2(2):e000132. doi:10.1136/esmoopen-2016-000132
   PubMed Web of Science ®Google Scholar
• Sasso FC, Pafundi PC, Simeon V, et al. Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease. Cardiovasc Diabetol. 2021;20(1):145. doi:10.1186/s12933-021-01343-1
   PubMed Web of Science ®Google Scholar
• Stenson PD, Mort M, Ball EV, et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet. 2017;136(6):665–677. doi:10.1007/s00439-017-1779-6
   PubMed Web of Science ®Google Scholar
• Landrum MJ, Chitipiralla S, Brown GR, et al. ClinVar: improvements to accessing data. Nucleic Acids Res. 2020;48(D1):D835–844. doi:10.1093/nar/gkz972
   PubMed Web of Science ®Google Scholar
• Patel DK, Strong J. The pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: beyond the glycemic benefit. Diabetes Ther. 2019;10(5):1771–1792. doi:10.1007/s13300-019-00686-z
   Web of Science ®Google Scholar
• Shao SC, Chang KC, Lin SJ, et al. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients. Cardiovasc Diabetol. 2020;19(1):17. doi:10.1186/s12933-020-0990-2
   Web of Science ®Google Scholar
• Tang L, Chang SJ, Chen CJ, Liu JT. Non-invasive blood glucose monitoring technology: a review. Sensors. 2020;20(23):1–32. doi:10.3390/s20236925
   Web of Science ®Google Scholar
• Sirdah MM, Reading NS. Genetic predisposition in type 2 diabetes: a promising approach toward a personalized management of diabetes. Clin Genet. 2020;98(6):525–547. doi:10.1111/cge.13772
   Web of Science ®Google Scholar
• Florez JC. Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool? Diabetologia. 2017;60(5):800–807. doi:10.1007/s00125-017-4227-1
   PubMed Web of Science ®Google Scholar
• Huang C, Florez JC. Pharmacogenetics in type 2 diabetes: potential implications for clinical practice. Genome. 2011;3(76). doi:10.1186/gm292
   Web of Science ®Google Scholar
• Klonoff DC. Personalized medicine for diabetes. J Diabetes Sci Technol. 2008;2(3):335–341. doi:10.1177/193229680800200301
   Google Scholar
• Maruthur NM, Gribble MO, Bennett WL, et al. The pharmacogenetics of type 2 diabetes: a systematic review. Diabetes Care. 2014;37(3):876–886. doi:10.2337/dc13-1276
   PubMed Web of Science ®Google Scholar